Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale. As examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.
This conference aims to bridge nanotechnology with clinical and pre-clinical cancer research, and to highlight recent applications in patient care. It will provide an overview of the latest developments in the field of cancer-related nanotechnologies. There will be many opportunities to present work, with lively poster sessions and eight proffered papers selected from submitted abstracts. Eight more high-scoring abstracts will be presented as 3 minute Poster Spotlight talks in the lecture theatre.
Who should attend?
The conference will be relevant for anyone who is interested in the application of nanotechnology in the context of cancer, from biologists through to engineers. We welcome participation from industry scientists as well as those within academia, from early-stage researchers through to senior scientists.
This conference aims to bridge nanotechnology with clinical and pre-clinical cancer research, and to highlight recent applications in patient care. It will provide an overview of the latest developments in the field of cancer-related nanotechnologies. There will be many opportunities to present work, with lively poster sessions and eight proffered papers selected from submitted abstracts. Eight more high-scoring abstracts will be presented as 3 minute Poster Spotlight talks in the lecture theatre.
Who should attend?
The conference will be relevant for anyone who is interested in the application of nanotechnology in the context of cancer, from biologists through to engineers. We welcome participation from industry scientists as well as those within academia, from early-stage researchers through to senior scientists.
